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Abstract
Background: Age at breast cancer diagnosis is a known prognostic factor. Previously, several groups including ours
have shown that young age at diagnosis is associated with higher prevalence of basal-like tumors and aggressive
tumor phenotypes. Yet the impact of age at diagnosis on the genomic landscape of breast cancer remains unclear.
In this study, we examined the pattern of somatic mutations, chromosomal copy number variations (CNVs) and
transcriptomic profiles in young and elderly breast cancer patients.
Methods: Analyses were performed on The Cancer Genome Atlas (TCGA) dataset. Patients with metastatic disease
at diagnosis, classified as normal-like by PAM50 or had missing clinical information were excluded. Young patients
were defined as ≤45 years of age, while elderly patients were those ≥70 years of age at breast cancer diagnosis.
The remaining patients were classified as “intermediate”. We evaluated the association between age at diagnosis
and somatic mutations, CNV and gene expression in a logistic regression model adjusting for tumor size, nodal
status, histology and breast cancer subtype. All analyses were corrected for multiple testing using the
Benjamini–Hochberg approach.
Results: In this study, 125, 486 and 169 patients were ≤45, 46–69 and ≥70 years of age, respectively. Older patients had
more somatic mutations (n = 44 versus 35 versus 31; P = 0.0009) and more CNVs, especially in ductal tumors (P = 0.02).
Eleven mutations were independently associated with age at diagnosis, of which only GATA3 was associated with
young age (15.2 % versus 8.2 % versus 9 %; P = 0.003). Only two CNV events were independently associated with age,
with more chr18p losses in older patients and more chr6q27 deletions in younger ones. Younger age at diagnosis was
associated with higher expression of gene signatures related to proliferation, stem cell features and endocrine resistance.
Conclusions: Age adds a layer of biological complexity beyond breast cancer molecular subtypes, classic
pathological and clinical variables, worthy of further consideration in future drug development as we seek to
refine therapeutic strategies in the era of personalized medicine.
Keywords: Age, Breast cancer biology, Breast cancer in the elderly, Breast cancer in young patients, GATA3, Gene
expression, Mutations
Background
Young age at breast cancer diagnosis is a known poor
prognostic factor [1, 2]. Previous studies have indicated
higher prevalence of poorly differentiated, estrogen recep-
tor (ER)-negative and human epidermal growth factor re-
ceptor 2 (HER2)-positive tumors in women diagnosed at a
young age [3, 4]. Further genomic characterization has re-
vealed enrichment with basal-like tumors [5, 6]. While
these observations could well explain the poorer outcome
of young breast cancer patients compared to their older
counterparts, younger age remains an independent poor
determinant of long-term outcome [5]. This underscores
the need to further refine our understanding of the impact
of age on cancer biology, which could have relevant impli-
cations on patient management.
On the other hand, few data are available with respect
to the biological features of tumors arising in the elderly.
Currently, around 30–35 % of breast cancer patients
are over 70 years of age at the time of diagnosis and
this is expected to increase in the coming years [7].
While these patients appear to develop relatively more
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“indolent” tumors characterized by high endocrine recep-
tor expression [8], the late onset of these tumors may also
suggest accumulation of several genomic aberrations over
time, due to the stochastic nature of DNA damage in
eukaryotic cells during the replication process. Ac-
knowledging that morbidities other than cancer itself
often contribute to mortality of older patients [9], it
is very important to refine our understanding of the
biology of these tumors in an attempt to optimize
their management.
Previously, our group and others have published on
the differences at the transcriptomic level according to
age at diagnosis, investigating selected genes or pathways
[5, 6, 10]. However, we lack studies that evaluate the dif-
ferences at the DNA level. In the current study,we in-
vestigated for the first time the differences in somatic
mutations and copy number variations (CNVs) between
young and older breast cancer patients. In addition, we
evaluated the expression of thousands of relevant genomic
signatures at the RNA level.
Methods
Eligible patients
All analyses were performed on The Cancer Genome
Atlas (TCGA) publicly available dataset. Eligible patients
were those with non-metastatic disease who had complete
information on age at breast cancer diagnosis, tumor hist-
ology, tumor size and lymph node status. For each patient,
we determined the breast cancer molecular subtype using
PAM50 [11]. PAM50 classes were determined from the
TCGA RNA-Seq gene expression data using the genefu
package of the R/Bioconductor statistical package. Sam-
ples of patients classified as normal-like were excluded, as
they often represent an artifact due to limited tumor cellu-
larity and a large background of normal breast cells in the
sample [12].
Young patients were defined as ≤45 years of age, while
elderly patients were defined as those ≥70 years of age at
breast cancer diagnosis. The remaining patients were
classified as “intermediate”. Since the TCGA dataset is
publicly available, ethics committee approval was not
needed. In addition, neither patient informed consent
nor permission to use this data was required to perform
this analysis.
Genomic analysis
We evaluated three parameters: 1) somatic mutations
using exome sequencing; 2) somatic CNV; and 3) tran-
scriptomic profiles. We downloaded the data from the
TCGA online repository in February 2015.
In the current analysis, all somatic mutations were
considered apart from those referred to as “silent”
mutations. Somatic CNV was evaluated using array com-
parative genomic hybridization (CGH) data, available as
pre-processed, publicly available information and not vali-
dated by any other methodology. Segmented data were
used as input for Genomic Identification of Significant
Targets in Cancer, version 2.0 (GISTIC 2.0) and version
6.2 on the Broad Institute GenePattern cloud server to ob-
tain somatic focal and broad CNV events [13]. These were
then parsed in R. For focal events, only “high-level” focal
amplification events, defined as log2 ratio >0.9 were
retained, whereas focal losses were retained with log2
ratio >0.3 and with a Q value <0.25. Broad events,
defined as arm-level events encompassing 98 % or
more of a chromosome arm, were computed using
GISTIC as well.
For transcriptomic profiling, we used the RNA se-
quencing data to evaluate differences in transcriptomic
profiles according to age. Data were downloaded from
the TCGA online repository and RNA-Seq absolute ex-
pression values were log2 transformed before performing
the analyses.
Statistical analyses
The association between age groups, that is, young
(≤45 years), intermediate (46–49 years) and elderly pa-
tients (≥70 years), with clinicopathological characteristics
was evaluated using Pearson’s chi-squared test. The
Kruskal–Wallis test was used to compare the number of
mutations and CNVs according to age group. For muta-
tions that were represented in at least 5 % in any age
group, we evaluated their independent association
with age at diagnosis (as a continuous variable) in a
logistic regression model adjusting for tumor size (≤2 cm
versus >2 cm), nodal status (negative versus positive),
tumor histology (ductal versus lobular) and breast cancer
subtype (luminal-A versus luminal-B versus HER2 versus
basal). A similar model was used to evaluate the inde-
pendent association between age, CNV and gene expres-
sion using the Molecular Signatures Database (MSigDB;
PMID: 16199517). All analyses were corrected for multiple
testing using the Benjamini–Hochberg approach [14].
Results
A total of 780 patients from the TCGA dataset where
included, of whom 125, 486 and 169 were ≤45, 46–69
and ≥70 years of age, respectively. Transcriptomic
data was available for all patients, while 722 (92.5 %)
and 713 (91.4 %) had available somatic mutation and
CNV data, respectively.
Table 1 summarizes the main characteristics of patients.
As expected, young patients had less lobular cancer (7 %
versus 24 % versus 29 %; P <0.001), fewer node-negative
tumors (38 % versus 49 % versus 49 %; P = 0.05) and a
trend of more basal-like tumors (20 % versus 18 % versus
14 %; P = 0.16).
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Somatic mutations according to age
We found a significant association between age at diag-
nosis and the prevalence of somatic mutations. Median
number of somatic mutations in the young group was
31, compared to 35 and 44 in the intermediate and older
patient groups, respectively (P value = 0.0009). Figure 1
shows the four most prevalent somatic mutations in the
different age groups. PIK3CA and TP53 were the most
common somatic mutations, constituting around 50–
60 % of all mutations across the different age groups.
The striking difference between the three age groups
was for GATA3, which was the third most common
somatic mutation in young patients, constituting 15.2 %,
while TTN mutation was the third most frequent muta-
tion in the intermediate (15.1 %) and older patient
groups (29 %).
To evaluate the independent effect of age on the
prevalence of somatic mutations, we performed a logistic
regression analysis adjusted for tumor size, nodal status,
histology and breast cancer molecular subtype. We
found 11 mutations to be independently associated with
age at diagnosis (Table 2). All were associated with older
age at diagnosis, except GATA3, which was independ-
ently associated with breast cancer arising in young
women (15.2 % versus 8.2 % versus 9 %; P = 0.003, false
discovery rate (FDR) = 0.033).
Somatic CNV events according to age
We evaluated the prevalence of CNV events according
to age. We found a tendency of higher focal and broad
CNV in older patients (mean = 15), compared to 13.9
and 13.5 in the intermediate and younger age groups, re-
spectively (P = 0.2). The differences were more apparent
when restricting the analysis to patients with ductal car-
cinoma (mean CNV in older patients = 16.4 versus 14.9 in
intermediate versus 13.8 in young patients; P = 0.05). In a
logistic regression model, we found 13 CNV events to be
independently associated with age (Fig. 2, Additional
file 1). However, upon adjusting for multiple testing, only
two CNV events maintained a P value <0.05: chr18p loss
and chr6q27 deletion; the former was associated with tu-
mors diagnosed in older patients, while the latter was
more common in younger patients.
Gene expression differences according to age
We evaluated the association between age at diagnosis and
the expression of 10,296 gene expression signatures. In a
logistic regression model adjusted for tumor size, nodal
status, histology and breast cancer molecular subtype, we
found around 1,200 gene signatures to be independently
associated with age at diagnosis (FDR <0.05), mainly in
younger patients (Additional file 2). The main themes that
emerged from this analysis are summarized in Table 3 and
indicated higher expression of signatures related to prolif-
eration, stem cell and endocrine resistance in tumors aris-
ing at young age.
Table 1 Main characteristics of patients








Number 125 486 169
Tumor size
≤2 cm 30 (24 %) 135 (28 %) 43 (26 %) 0.64
>2 cm 95 (76 %) 351 (72 %) 126 (74 %)
Nodal status
Negative 47 (38 %) 241 (49 %) 83 (49 %) 0.05
Positive 78 (62 %) 245 (51 %) 86 (51 %)
Histology
Ductal 116 (93 %) 371 (76 %) 121 (71 %) <0.001
Lobular 9 (7 %) 95 (24 %) 48 (29 %)
PAM50 subtype
Luminal-A 44 (35 %) 200 (41 %) 70 (41 %) 0.16
Luminal-B 41 (33 %) 140 (29 %) 64 (38 %)
HER2 15 (12 %) 57 (12 %) 12 (7 %)
Basal 25 (20 %) 89 (18 %) 23 (14 %)
Fig. 1 Prevalence of somatic mutations according to age
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Discussion
This is the first analysis to explore the prevalence of
somatic mutations and CNV according to age. Our find-
ings indicate that age is associated with unique biological
features at the DNA level, independent of tumor stage,
histology and breast cancer molecular subtype. In
addition, age at diagnosis appears to impact the tumor
transcriptome confirming previous observations, but
also highlighting novel findings. While previous studies
provide ample information on the differences at the
pathological level according to age [2, 15], this study
provides further insights on differences at the genomic
Table 2 The independent association between age at diagnosis and somatic mutations
Young age Intermediate age Older age Logistic model FDR
(≤45 years, n = 118) (46–69 years, n = 449) (≥70 years, n = 155) (P value)a
Mutations independently associated with young age at diagnosis
GATA3 18 (15.2 %) 37 (8.2 %) 14 (9 %) 0.003 0.033
Mutations independently associated with older age at diagnosis
TTN 16 (13.5 %) 68 (15.1 %) 45 (29 %) 0.0003 0.01
KMT2D 1 (0.8 %) 9 (2 %) 9 (5.8 %) 0.0003 0.01
CSPP1 0 3 (0.6 %) 8 (5.1 %) 0.0002 0.01
FOXA1 1 (0.8 %) 6 (1.3 %) 9 (5.8 %) 0.0009 0.013
XIST 0 6 (1.3 %) 9 (5.8 %) 0.0008 0.013
KMT2C 4 (3.3 %) 26 (5.7 %) 18 (11.6 %) 0.002 0.027
SYNE2 3 (2.5 %) 16 (3.5 %) 13 (8.3 %) 0.005 0.033
SPEN 2 (1.6 %) 13 (2.8 %) 12 (7.7 %) 0.005 0.033
USP34 1 (0.8 %) 12 (2.6 %) 9 (5.8 %) 0.004 0.033
ANK2 0 11 (2.4 %) 9 (5.8 %) 0.007 0.043
aAnalysis adjusted for age, tumor size, nodal status, histology and breast cancer subtype. Only mutations with a minimum prevalence of 5 % in at least one age
group is included. FDR, false discovery rate
Fig. 2 Copy number variation (CNV) events that are significantly different according to age (P <0.05 in the adjusted logistic regression model).
Green represents younger patients (≤45 years), blue represents intermediate (46–69 years) and red represents elderly patients (≥70 years). The Y
access shows the percentage and indicates the direction of CNV gain (above 0) or loss (below 0). *Aberrations that show a false discovery rate
(FDR) <0.05
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level as well. This is also in line with previous studies
that showed changes in the normal breast at both the
genomic and epigenetic level between young and older
women, including changes in genes that are known to be
relevant in breast carcinogenesis [16, 17]. Such evidence
may suggest the need to explore treatment strategies in
patients diagnosed at extremes of age based on their
unique molecular makeup.
Different themes emerged from our analysis. First,
older patients have more mutations and CNV events.
This is likely a reflection of more genomic errors accu-
mulated in the DNA as women age. We found that
several somatic mutations were independently associated
with older age at diagnosis. Of particular relevance, the
high prevalence of KMT2D mutations. Since this gene
was recently shown to be involved in tumor proliferation
and cell migration [18], we speculate that KMT2D muta-
tions may alter breast cancer behavior. Another finding
is the high prevalence of FOXA1 mutations. The latter is
required for ER-alpha as a cofactor for chromatin bind-
ing and constitutes a major proliferative and survival
pathway for luminal-A tumors [19], which are common
in older patients [20]. Nevertheless, it is yet to be deter-
mined whether these mutations and/or others represent
key driver mutations of tumors arising in older patients
and the optimal way of targeting them.
On the other hand, GATA3 mutation was the main
somatic event that characterized tumors arising at a
younger age, which could have relevant clinical implica-
tions. GATA3 is an essential component of the ER
complex and its mutations are likely to affect ER-
regulated transcriptional activity [21, 22]. GATA3 dir-
ectly upregulates ER-alpha and other proto-oncogenes
suggesting that it may promote tumorigenesis in luminal
cancer [23]. Preclinical data indicate that mutations in
GATA3 also affect ER binding to DNA [22, 24], modu-
late response of breast cancer cells to estrogen signaling
[25], could promote tumor growth [21, 26] and could be
associated with endocrine resistance [25]. This is of ex-
treme relevance, since the poor prognosis associated
with younger age at diagnosis has been mainly observed
in patients with ER-positive breast cancers [3, 5]. We
could speculate that the higher prevalence of GATA3
mutations in these patients may render these patients
more resistant to endocrine therapy. Our transcriptomic
analyses also highlights the high expression of endocrine
resistance signatures in younger patients, thus suggest-
ing that endocrine resistance is an important hallmark
of tumors arising in young women, worthy of further ex-
ploration. Of note, previous preclinical studies have
shown that GATA expression (not mutation) results in
reversal of the epithelial-mesenchymal transition (EMT)
and induction of differentiation in basal-like tumors
[27, 28]. Therefore, it is the loss of GATA3 expres-
sion that was suggested to contribute to the aggres-
siveness of basal-like tumors. Using our dataset, we
found that GATA3 expression is higher in patients
with GATA3 mutation (data not shown). These mutations
were mostly exclusive in patients with ER-positive breast
cancer. Thus, based on our findings, we cannot assume
that the higher rate of GATA3 mutations observed in
younger patients is linked to the known increased inci-
dence of basal-like tumors in these patients.
CNVs are genomic events that are regarded as highly
biologically relevant in breast cancer [29] and we found
two events, more chr18p losses and chr6q27 deletions,
to be independently associated with age at diagnosis.
chr18p loss was more common in older patients and
previous data indicated that it is associated with higher
risk of recurrence [30]. Of note, chr18 also harbors
SMAD4, which is a known tumor suppressor gene and
has been shown to be associated with poor prognosis in
several tumor types when lost [31–33]. On the other
hand, very little is known on its significance in breast
cancer. A previous study showed that chromosome 6 is
frequently rearranged in breast cancer, particularly at
three regions, including 6q27 [34]. In addition, chr6q27
deletion appears to be more prevalent in tumors with
aggressive features [34]. This may suggest that this re-
gion could harbor relevant tumor suppressor genes that
may contribute to the aggressive nature of tumors aris-
ing in younger patients.
Another key point emerging from our study is the ex-
istence of relevant gene expression differences according
Table 3 Selected gene expression signatures that are highly











Regulation of cell cycle 1.43E-11 1.47E-07








aMore than one signature; bmodel adjusted for tumor size, nodal status, tumor
histology and breast cancer subtype. FDR, false discovery rate
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to age. Previously, we showed that tumors arising in young
women are enriched with stem cell-related genes [5]. In
addition, Pirone et al. have shown that pathways impli-
cated in maintaining stem cell dynamics, Wnt/β-catenin
and ephrin receptor signaling [35, 36] were differentially
expressed in the normal breast between young and older
women [16]. The current analysis corroborates this associ-
ation and suggests that targeting the stem cell component
is a strategy that deserves exploration in young breast can-
cer patients. Currently, there are several drugs in develop-
ment, such as Notch inhibitors that are known to target
the stem cell compartment [37]. Of note, in the current
analysis, we found high expression of signatures related to
Notch signaling pathways (Table 3) in young breast cancer
patients, which may suggest the potential relevance of ex-
ploring such strategies in younger patients.
We recently initiated a preoperative window trial
evaluating the role of targeting RANKL, a known stem
cell regulator [38] and in which we have previously
shown to be highly expressed in tumors arising at a young
age [5, 39]. In this trial (D-BEYOND; NCT01864798), all
patients are premenopausal and receive the anti-RANKL
monoclonal antibody denosumab before surgery. The
aim is to evaluate the impact of RANKL inhibition on
several biological processes, including proliferation,
stem cell markers, immune-related markers, and many
others. The trial has recruited >50 % of its target accrual
and represents a proof of concept that could open the
door for designing future trials in women diagnosed at
extremes of age, based on a better understanding of the
biology of their tumors.
Conclusion
In conclusion, the present work shows that tumors aris-
ing at different ages are biologically distinct, not only at
the protein level, as previously shown, but also at the
RNA and DNA levels. This includes aberrations in rele-
vant cancer-related genes. While current treatment
decision-making is mainly based on tumor stage and
breast cancer subtype, our analysis suggests that age
adds a layer of biological complexity, worthy of investigat-
ing tailored therapeutic strategies in specific age groups.
This could further result in refining therapeutic strategies
as we embark on an era of personalized medicine.
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